FDA 483 - Ipca Laboratories Limited - December 01, 2025

An FDA inspection of Ipca Laboratories Limited, an API manufacturer in Palghar, India, conducted from December 1st to December 5th, 2025, revealed significant observations detailed in an FDA 483 document. The inspection highlighted deficiencies in Good Manufacturing Practices (GMP) pertaining to facility maintenance, analytical method validation, and controls for preventing material carryover. Specifically, the agency observed that manufacturing clean rooms, including areas for US market products, were not adequately maintained to prevent contamination. Issues included a large piece of peeling paint in an open processing area and numerous cracks on walls and ceilings in the weighing and packing area where APIs are exposed, indicating a failure to identify and rectify these during routine maintenance. Furthermore, the suitability of analytical test methods was found deficient. Verification studies for assay and organic impurities lacked scientific data to support the acceptable HPLC column temperature range, which could impact result accuracy. This was underscored by an out-of-specification investigation where retention time shifts affected analysis. Finally, Ipca Laboratories lacked adequate controls to minimize residual material carryover between batches, failing to define maximum campaign lengths for API manufacturing and unable to scientifically demonstrate that residues were not transferred during extended production campaigns. The company is required to address these observations through corrective actions to ensure compliance with regulatory standards.